Key facts
- Notable investors include Diamond Medino Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for RIBS (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for RIBS (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RIBS (Drug Discovery)
Operator of a custom-made treatment company intended for aortic arch aneurysms. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2025
- Employees
- 10
- Ownership
- Privately Held (backing)
RIBS (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RIBS (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RIBS (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.